title: [Clinical evaluation of norfloxacin in pediatrics].
abstract: We have evaluated the effectiveness and safety of norfloxacin (NFLX) in 18 children with infectious diseases. Doses ranging from 5.6 to 18.8 mg/kg/day for t.i.d. or q.i.d. were used. The causative bacteria were Campylobacter jejuni in 3 cases, Salmonella typhimurium in 1, Staphylococcus aureus in 2, Haemophilus influenzae in 1 and unknown in 11 cases. Except 1 strain of S. aureus, all the bacteria mentioned above were eradicated. Clinical effects were excellent in 8, good in 8, poor in 2, and the total efficacy rate was 88.9%. No side effects nor abnormal laboratory test results were observed. These results have shown that the NFLX is a usefull drug for infectious diseases in the pediatric field.
authors.affiliation: Department of Pediatrics, Kagawa Children Hospital, National Sanatorium.
authors.forename: T
authors.initials: T
authors.lastname: Okada
authors.forename: S
authors.initials: S
authors.lastname: Furukawa
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013607:Tablets
chemical_list: D013607:Tablets; D009643:Norfloxacin